Atria Investments Inc Acquires 1,460 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Atria Investments Inc raised its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 8.0% in the 3rd quarter, Holdings Channel.com reports. The fund owned 19,609 shares of the medical technology company’s stock after buying an additional 1,460 shares during the period. Atria Investments Inc’s holdings in Alphatec were worth $109,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ATEC. Net Worth Advisory Group acquired a new stake in shares of Alphatec in the 3rd quarter valued at approximately $76,000. Comerica Bank lifted its holdings in Alphatec by 64.8% during the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock valued at $89,000 after purchasing an additional 2,534 shares during the last quarter. Van ECK Associates Corp increased its position in Alphatec by 57.0% during the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after buying an additional 6,998 shares during the period. Tempus Wealth Planning LLC bought a new position in Alphatec during the 3rd quarter worth $107,000. Finally, Stephens Inc. AR increased its position in shares of Alphatec by 51.4% in the third quarter. Stephens Inc. AR now owns 21,743 shares of the medical technology company’s stock worth $121,000 after purchasing an additional 7,382 shares during the period. 66.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research report on Thursday, October 31st. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a report on Friday, August 30th. Wells Fargo & Company reduced their target price on Alphatec from $26.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Lake Street Capital cut their price target on Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $13.00 target price on shares of Alphatec in a research report on Thursday, October 31st. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.11.

Alphatec Trading Down 1.5 %

Shares of Alphatec stock opened at $10.06 on Monday. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $17.34. The firm has a market cap of $1.43 billion, a PE ratio of -7.86 and a beta of 1.31. The stock has a fifty day moving average price of $6.71 and a 200-day moving average price of $8.22. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.